Featured Article

Researchers have presented a new technique to identify drug targets linked to abnormal protein phase separation in diseases such as Alzheimer's.

Precision Oncology Today

Magazine

Can Immunotherapy be Democratized?

In 2012, 6-year-old Emily Whitehead’s acute lymphoblastic leukemia returned, and no traditional treatment options remained. So she became the first child to receive CAR-T...
antibodies

Charging to the Frontline

Bispecific antibodies show promise in delivering immunotherapy with limited side effects and high response rates.
Mountain Forest Hiker Illustration

Cancer: The Next Microbiome Frontier

Three therapeutic regulatory approvals in less than a year signal that the promise of the human microbiome may finally be paying off. All of...

Trending on Inside Precision Medicine

Translucent robotic looking hand holding a test tube next to a screen showing code and a digital pill to symbolize the use of AI to develop new protein phase separation drugs

AI-Driven Approach Identifies Drug Targets for Neurodegenerative Disorders

Researchers have presented a new technique to identify drug targets linked to abnormal protein phase separation in diseases such as Alzheimer's.
Brain MRI Scan of Healthy Male  ( Magnetic Resonance Imaging) High Resolution

AcuraStem and Takeda Ink $580M Deal That Includes ALS Targets

Takeda and AcuraStem will jointly develop and commercialize AcuraStem's PIKFYVE targeted therapeutics for neurodegenerative diseases including ALS and frontotemporal dementia.
Multiple Sclerosis Nerve Disorder illustrated as a head with neurons fluorescing in the brain and damaged neurons to the right hand side

Stem Cell Transplantation Suitable for Treating Relapsing-Remitting MS

New research led by investigators at Uppsala University in Sweden shows emerging evidence that autologous hematopoietic stem cell transplantation (aHSCT) may be a suitable treatment for relapsing-remitting multiple sclerosis (MS).

Daily News

Related Content

Inside Precision Medicine